Overview of Polycythemia Vera Biology Essay
Marchioli et al. in the Journal that a hematocrit target of less, for therapeutic phlebotomy, reduces the risk of thrombosis in patients with polycythemia vera. In the genomic era, r. Introduction. Over the past century, polycythemia vera PV has undergone substantial changes in concept and diagnostic criteria. The disease was first described by Louis Henri Vaquez (1860-1936) and further elaborated by William Osler (1849-1919). Dameshek 1900-1969 included PV as one of the disease overviews. Polycythemia vera PV is a JAK2 mutated myeloproliferative neoplasm characterized by clonal erythrocytosis. Other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculation disorders, and an increased risk of thrombosis and progression to blood tests. If you have polycythemia vera, blood tests may show: more red blood cells than normal and sometimes an increase in the number of platelets or white blood cells; a greater percentage of red blood cells that make up the total blood volume; the hematocrit measurement; increased iron levels. -rich protein in red blood cells that carries, erythrocytosis describes too many red blood cells having a solid part in relation to plasma, the liquid part. Erythrocytosis causes you to have a high hematocrit and/or hemoglobin level. Hematocrit Levels: Hematocrit is the number of red blood cells you have. Hemoglobin Levels: Hemoglobin is an essential protein found in red blood,